These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21270116)

  • 1. FXR activation inhibits inflammation and preserves the intestinal barrier in IBD.
    Wildenberg ME; van den Brink GR
    Gut; 2011 Apr; 60(4):432-3. PubMed ID: 21270116
    [No Abstract]   [Full Text] [Related]  

  • 2. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.
    Gadaleta RM; van Erpecum KJ; Oldenburg B; Willemsen EC; Renooij W; Murzilli S; Klomp LW; Siersema PD; Schipper ME; Danese S; Penna G; Laverny G; Adorini L; Moschetta A; van Mil SW
    Gut; 2011 Apr; 60(4):463-72. PubMed ID: 21242261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease.
    Stojancevic M; Stankov K; Mikov M
    Can J Gastroenterol; 2012 Sep; 26(9):631-7. PubMed ID: 22993736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IBD pathogenesis in 2014: Molecular pathways controlling barrier function in IBD.
    Atreya R; Neurath MF
    Nat Rev Gastroenterol Hepatol; 2015 Feb; 12(2):67-8. PubMed ID: 25446731
    [No Abstract]   [Full Text] [Related]  

  • 5. Importance of disrupted intestinal barrier in inflammatory bowel diseases.
    Salim SY; Söderholm JD
    Inflamm Bowel Dis; 2011 Jan; 17(1):362-81. PubMed ID: 20725949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease?
    Ogilvie LA; Jones BV
    Gut; 2012 Nov; 61(11):1642-3. PubMed ID: 22490526
    [No Abstract]   [Full Text] [Related]  

  • 7. Current medical therapy for chronic inflammatory bowel diseases.
    Tamboli CP
    Surg Clin North Am; 2007 Jun; 87(3):697-725. PubMed ID: 17560421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD.
    Klepsch V; Moschen AR; Tilg H; Baier G; Hermann-Kleiter N
    Front Immunol; 2019; 10():1070. PubMed ID: 31139192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for PPAR gamma in IBD? Yes, no, maybe.
    Wu GD
    Gastroenterology; 2003 May; 124(5):1538-42. PubMed ID: 12730893
    [No Abstract]   [Full Text] [Related]  

  • 10. Lymphatic dysregulation in intestinal inflammation: new insights into inflammatory bowel disease pathomechanisms.
    Becker F; Yi P; Al-Kofahi M; Ganta VC; Morris J; Alexander JS
    Lymphology; 2014 Mar; 47(1):3-27. PubMed ID: 25109166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
    Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
    Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse models of inflammatory bowel disease for investigating mucosal immunity in the intestine.
    Bamias G; Arseneau KO; Cominelli F
    Curr Opin Gastroenterol; 2017 Nov; 33(6):411-416. PubMed ID: 28901966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug development in IBD: from novel target identification to early clinical trials.
    Danese S; Fiocchi C; Panés J
    Gut; 2016 Aug; 65(8):1233-9. PubMed ID: 27196598
    [No Abstract]   [Full Text] [Related]  

  • 14. The glucocorticoid budesonide has protective and deleterious effects in experimental colitis in mice.
    Ocón B; Aranda CJ; Gámez-Belmonte R; Suárez MD; Zarzuelo A; Martínez-Augustin O; Sánchez de Medina F
    Biochem Pharmacol; 2016 Sep; 116():73-88. PubMed ID: 27431777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.
    Trivedi I; Hanauer SB
    Expert Opin Drug Saf; 2015; 14(12):1915-34. PubMed ID: 26559664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential role of nutraceutical compounds in inflammatory bowel disease.
    Larussa T; Imeneo M; Luzza F
    World J Gastroenterol; 2017 Apr; 23(14):2483-2492. PubMed ID: 28465632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine.
    Gadaleta RM; Oldenburg B; Willemsen EC; Spit M; Murzilli S; Salvatore L; Klomp LW; Siersema PD; van Erpecum KJ; van Mil SW
    Biochim Biophys Acta; 2011 Aug; 1812(8):851-8. PubMed ID: 21540105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats.
    Ceulemans LJ; Verbeke L; Decuypere JP; Farré R; De Hertogh G; Lenaerts K; Jochmans I; Monbaliu D; Nevens F; Tack J; Laleman W; Pirenne J
    PLoS One; 2017; 12(1):e0169331. PubMed ID: 28060943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile salt supplementation acts via the farnesoid X receptor to alleviate lipopolysaccharide-induced intestinal injury.
    Zahiri HR; Perrone EE; Strauch ED
    Surgery; 2011 Sep; 150(3):480-9. PubMed ID: 21878234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel drug delivery strategies for the treatment of inflammatory bowel disease.
    Kesisoglou F; Zimmermann EM
    Expert Opin Drug Deliv; 2005 May; 2(3):451-63. PubMed ID: 16296767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.